Gainers
- Oncolytics Biotech (NASDAQ:ONCY) shares increased by 19.4% to $1.48 during Friday's pre-market session. The market value of their outstanding shares is at $125.5 million.
- Intensity Therapeutics (NASDAQ:INTS) shares increased by 17.27% to $0.37. The market value of their outstanding shares is at $15.5 million.
- Nyxoah (NASDAQ:NYXH) stock rose 14.24% to $7.3. The company's market cap stands at $239.2 million.
- Accuray (NASDAQ:ARAY) stock rose 13.55% to $2.1. The company's market cap stands at $208.4 million.
- Talkspace (NASDAQ:TALK) shares rose 12.37% to $3.27. The company's market cap stands at $487.3 million.
- INVO Fertility (NASDAQ:IVF) shares rose 11.53% to $0.9. The company's market cap stands at $3.5 million.
Losers
- CARISMA Therapeutics (NASDAQ:CARM) shares declined by 36.4% to $0.17 during Friday's pre-market session. The company's market cap stands at $11.4 million.
- Alaunos Therapeutics (NASDAQ:TCRT) stock fell 17.27% to $3.3. The market value of their outstanding shares is at $6.5 million.
- VolitionRX (AMEX:VNRX) stock declined by 15.62% to $0.51. The company's market cap stands at $64.5 million.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 12.39% to $9.55. The company's market cap stands at $6.7 million.
- Inventiva (NASDAQ:IVA) stock declined by 12.12% to $4.86. The company's market cap stands at $769.1 million.
- OrthoPediatrics (NASDAQ:KIDS) stock fell 11.93% to $15.81. The company's market cap stands at $450.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BDRXBiodexa Pharmaceuticals PLC
$9.40-13.8%
CARMCARISMA Therapeutics Inc
$0.1181-56.9%
INTSIntensity Therapeutics Inc
$0.2857-9.96%
IVAInventiva SA
$4.88-11.8%
IVFINVO Fertility Inc
$0.7403-8.25%
KIDSOrthoPediatrics Corp
$15.52-13.5%
NYXHNyxoah SA
$6.897.82%
ONCYOncolytics Biotech Inc
$1.17-5.65%
TALKTalkspace Inc
$3.003.09%
TCRTAlaunos Therapeutics Inc
$3.23-19.1%
VNRXVolitionRX Ltd
$0.4695-21.8%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.